Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on durvalumab eligibility and safety profile-MedSci.cn

Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on durvalumab eligibility and safety profile

Cortiula, F; De Ruysscher, D; Dursun, S; Steens, M; Bootsma, G; Canters, R; Rinaldi, I; Taasti, VT; Houben, R; Reynders, K; Peeters, S; Angrisani, A; Hattu, D; Hendriks, L

ANNALS OF ONCOLOGY, 2022; 33 (): S85

科室
- - 订阅+
  - 更多科室
工具
服务